Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Solange Peters*, Eric Angevin, Teresa Alonso-Gordoa, Kristoffer Rohrberg, Ignacio Melero, Begoña Mellado, Jose-Luis Perez-Gracia, Josep Tabernero, Celine Adessi, Christophe Boetsch, Carl Watson, Joseph Dal Porto, David Dejardin, Christopher Del Nagro, Valeria Nicolini, Stefan Evers, Christian Klein, Barbara Leutgeb, Pavel Pisa, Eva RossmannJosé Saro, Pablo Umana, Jehad Charo, Volker Teichgräber, Neeltje Steeghs

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Fingerprint

Dive into the research topics of 'Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science